Table 1.
Patient characteristics.
| Variable | N (% of total) | Total group N = 376 | VKA users N = 77 (20.5%) | No VKA users N = 299 (79.5%) | P-value |
|---|---|---|---|---|---|
| Mean age, years (SD) | 376 (100) | 71.2 (SD 13.5) | 77.7 (SD 9.1) | 69.6 (SD 14.0) | <0.001 |
| Sex, male, n (%) | 376 (100) | 200 (53.3) | 42 (54.5) | 158 (52.8) | 0.889 |
| Hypertension, n (%) | 372 (99.0) | 220 (59.1) | 64 (83.1) | 156 (52.9) | <0.001 |
| Smoking, n (%) | 238 (63.3) | 63 (26.5) | 10 (20.4) | 53 (28.0) | 0.369 |
| Hypercholesterolemia, n (%) | 359 (95.5) | 146 (40.7) | 36 (48) | 110 (38.7) | 0.186 |
| Diabetes mellitus, n (%) | 373 (99.2) | 49 (13.1) | 14 (18.2) | 35 (11.8) | 0.200 |
| VKA duration of treatment in months, median (IQR)* | – | – | 35 (16.5–69.5) | – | – |
| High ICAC score, n (%) | 376 (100) | 87 (23.1) | 25 (32.5) | 62 (20.7) | 0.043 |
VKA, vitamin K antagonist; ICAC, intracranial carotid artery calcification; SD, standard deviation; IQR, interquartile range.
*
Missing in four patients.